Brightening The Future of  People Facing Challenges of Cancers
The Sun in Asia

Specialized Pharmaceutical Company in Oncology

We keep challenging

Thisi is Solasia

Product Pipeline – thinking each of you

Product Pipeline

For living brilliant future together

What Solasia seeks for

Development Strategy

  • Solasia
  • Other Companies

Pharmaceuticals

    • Pipeline Code
    • Estimated Initial indication
    • Originator
  • Pre-
    clinical
  • Clinical Study
    Phase 1
  • Clinical Study
    Phase 2
  • Clinical Study
    Phase 3
  • NDA
  • Approval
  • Launch
  • Partner
  • SP-01

    Chemotherapy Induced Nausea and Vomiting

    ProStrakan(Kyowa Kirin)
    overview
  • China
    US, EU, over 10 countries (Sancuso® by other companies)
  • Kyowa Hakko Kirin :
    Hong Kong, Macau, Taiwan, Malaysia, Singapore
    Lee’s Pharma:
    China Mainland w/o Beijing, Shanghai, Guangzhou, Hong Kong and Macau
  • SP-02

    Peripheral T-Cell Lymphoma

    ZIOPHARM Oncology, Inc
    overview
  • Japan, Korea, Taiwan, HK (Phase II, pivotal Study)
    China (Phase II/III, pivotal study preparation)
    US (Phase IIA, completion)
    EU (Pre-clinical, completion)
  • Meiji Seika Pharma :
    Japan

Medical Device

    • Pipeline Code
    • Estimated Initial indication
    • Originator
  • Pre-
    clinical
  • Clinical Study
  • NMDA
  • Approval
  • Launch
  • Partner
  • SP-03

    Pain associated oral mucositis

    Camurus AB
    overview
  • Japan
    China
    US, EU, over 6 countries (episil® by other companies)
  • Meiji Seika Pharma :
    Japan
    Lee’s Pharma:
    China Mainland w/o Beijing, Shanghai, Guangzhou and Taiwan

Pharmaceuticals

Pipeline Code
SP-01
Estimated Initial indication
Chemotherapy Induced Nausea and Vomiting
Originator
ProStrakan(Kyowa Kirin)
overview
  • Pre-
    clinical
  • Clinical Study
    Phase 1
  • Clinical Study
    Phase 2
  • Clinical Study
    Phase 2
  • NDA - Approval - Launch
China (Solasia)
US, EU, over 10 countries(Sancuso® by other companies)
Partner
Kyowa Hakko Kirin :
Hong Kong, Macau, Taiwan, Malaysia, Singapore
Lee’s Pharma:
China Mainland w/o Beijing, Shanghai, Guangzhou, Hong Kong and Macau
Pipeline Code
SP-02
Estimated Initial indication
Peripheral T-Cell Lymphoma
Originator
ZIOPHARM Oncology, Inc.
overview
  • Pre-
    clinical
  • Clinical Study
    Phase 1
  • Clinical Study
    Phase 2
  • Clinical Study
    Phase 3
  • NDA - Approval - Launch
Japan, Korea, Taiwan, HK(Phase II, pivotal Study)
China(Phase II/III, pivotal study preparation)
US(Phase IIA, completion)
EU(Pre-clinical, completion)
Partner
Meiji Seika Pharma :
Japan

Medical Device

Pipeline Code
SP-03
Estimated Initial indication
Pain associated oral mucositis
Originator
Camurus AB
overview
  • Pre-
    clinical
  • Clinical
    Study
  • NMDA
  • Approval - Launch
Japan
China
US, EU, over 6 countries (episil® by other companies)
Partner
Meiji Seika Pharma :
Japan
Lee’s Pharma:
China Mainland w/o Beijing, Shanghai, Guangzhou and Taiwan

Page Top

SELECT YOUR LANGUAGE